Linked Life Data

16088988

Source:http://linkedlifedata.com/resource/pubmed/id/16088988

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-8-8
pubmed:abstractText
Basic fibroblast growth factor (bFGF) has been known to stimulate the regeneration of a number of tissues including cartilage, nerve, skin, liver, and blood vessel. Delivery of bFGF for a long period in a controlled manner would enhance stimulative effects. The purpose of the present study is to test the hypothesis that the kinetics of bFGF release from fibrin gels could be controlled with heparin and concentrations of fibrinogen and thrombin. The kinetics of bFGF release from fibrin gels with various concentrations of fibrinogen, thrombin, and heparin was determined. The bioactivity of bFGF released from fibrin gels was assessed using dermal fibroblast cell culture. To examine the therapeutic potential of the bFGF delivery system, bFGF-loaded fibrin gels were injected into mouse ischemic limbs. The addition of heparin to fibrin gels decreased the bFGF release rate. As the thrombin content in fibrin gels increased, the bFGF release rate significantly decreased. Similarly, increased concentration of fibrinogen in fibrin gels decreased the bFGF release rate. Basic FGF released from fibrin gels exhibited significantly higher extents of fibroblast growth than bFGF added in a free form daily into the culture medium, suggesting that the fibrin gels may stabilize the bFGF bioactivity. Immunohistological analysis of mouse ischemic limbs indicated that the microvessel density was much higher in the ischemic limbs treated with injection of bFGF-loaded fibrin gels than in the ischemic limbs with no treatment. This study showed that the rate of bFGF release from fibrin gels can be controlled and that the bFGF delivery system has therapeutic potentials for angiogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0168-3659
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
249-59
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16088988-Angiogenesis Inhibitors, pubmed-meshheading:16088988-Animals, pubmed-meshheading:16088988-Anticoagulants, pubmed-meshheading:16088988-Drug Delivery Systems, pubmed-meshheading:16088988-Drug Implants, pubmed-meshheading:16088988-Female, pubmed-meshheading:16088988-Fibrin, pubmed-meshheading:16088988-Fibrinogen, pubmed-meshheading:16088988-Fibroblast Growth Factor 2, pubmed-meshheading:16088988-Gels, pubmed-meshheading:16088988-Hemostatics, pubmed-meshheading:16088988-Heparin, pubmed-meshheading:16088988-Humans, pubmed-meshheading:16088988-Ischemia, pubmed-meshheading:16088988-Kinetics, pubmed-meshheading:16088988-Male, pubmed-meshheading:16088988-Mice, pubmed-meshheading:16088988-Mice, Inbred C57BL, pubmed-meshheading:16088988-Neovascularization, Pathologic, pubmed-meshheading:16088988-Thrombin
pubmed:year
2005
pubmed:articleTitle
Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin.
pubmed:affiliation
Department of Chemical Engineering, Hanyang University, Seoul, Republic of Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't